Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer.

Breast cancer survivors Chemotherapy-induced peripheral neuropathy Physical exercise Symptom management

Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
07 May 2024
Historique:
received: 26 11 2023
accepted: 10 04 2024
medline: 7 5 2024
pubmed: 7 5 2024
entrez: 7 5 2024
Statut: aheadofprint

Résumé

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of neurotoxic chemotherapy. Exercise activates neuromuscular function and may improve CIPN. We examined the association between exercise and CIPN symptoms in breast cancer survivors. In a retrospective cross-sectional study, we included patients completing a survey assessing exercise exposure and neuropathy symptoms in a tertiary cancer center survivorship clinic. We evaluated exercise duration and intensity using a standardized questionnaire quantified in metabolic equivalent tasks (MET-h/wk). We defined exercisers as patients meeting the National Physical Activity Guidelines' criteria. We used multivariable logistic regressions to examine the relationship between exercise and CIPN and if this differed as a function of chemotherapy regimen adjusting for age, gender, and race. We identified 5444 breast cancer survivors post-chemotherapy (median age 62 years (interquartile range [IQR]: 55, 71); median 4.7 years post-chemotherapy (IQR: 3.3, 7.6)) from 2017 to 2022. CIPN overall prevalence was 34% (95% confidence interval [CI]: 33%, 36%), 33% for non-taxane, and 37% for taxane-based chemotherapy. CIPN prevalence was 28% (95% CI: 26%, 30%) among exercisers and 38% (95% CI: 37%, 40%) among non-exercisers (difference 11%; 95% CI: 8%, 13%; p < 0.001). Compared to patients with low (<6 MET-h/wk) levels of exercise (42%), 11% fewer patients with moderate (6-20.24 MET-h/wk) to high (>20.25 MET-h/wk) levels of exercise reported CIPN. Exercise was associated with reduced prevalence of all CIPN symptoms regardless of chemotherapy type. CIPN may persist several years following chemotherapy among patients with breast cancer but is significantly reduced by exercise in a dose-dependent manner.

Identifiants

pubmed: 38713289
doi: 10.1007/s10549-024-07342-6
pii: 10.1007/s10549-024-07342-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
ID : 5R25 CA020449
Pays : United States
Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA248563
Pays : United States

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13(1):27–46
pubmed: 18346229 doi: 10.1111/j.1529-8027.2008.00156.x
Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377–387
pubmed: 21814197 doi: 10.1038/clpt.2011.115
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470
pubmed: 25261162 doi: 10.1016/j.pain.2014.09.020
Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774
pubmed: 21128110 doi: 10.1007/s10549-010-1278-0
Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M et al (2013) Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 18(1):132–138
pubmed: 22105895 doi: 10.1007/s10147-011-0352-x
Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D et al (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 144(6):895–903
pubmed: 19170677 doi: 10.1111/j.1365-2141.2008.07573.x
Kautio AL, Haanpää M, Kautiainen H, Kalso E, Saarto T (2011) Burden of chemotherapy-induced neuropathy—a cross-sectional study. Support Care Cancer 19(12):1991–1996
pubmed: 21080201 doi: 10.1007/s00520-010-1043-2
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437
pubmed: 24590861 doi: 10.3322/caac.21204
Autissier E (2019) Chemotherapy-induced peripheral neuropathy: association with increased risk of falls and injuries. Clin J Oncol Nurs 23(4):405–410
pubmed: 31322611 doi: 10.1188/19.CJON.405-410
Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol 38(28):3325–3348
pubmed: 32663120 doi: 10.1200/JCO.20.01399
Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81(6):772–781
pubmed: 28486769 pmcid: 5656281 doi: 10.1002/ana.24951
Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848
pubmed: 22482054 pmcid: 3312207
Farshchian N, Alavi A, Heydarheydari S, Moradian N (2018) Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 82(5):787–793
pubmed: 30105459 doi: 10.1007/s00280-018-3664-y
Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, Kuroda H, Nagamachi Y, Konuma Y, Fujimi A et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20(5):866–871
pubmed: 25762165 doi: 10.1007/s10147-015-0810-y
McCrary JM, Goldstein D, Sandler CX, Barry BK, Marthick M, Timmins HC, Li T, Horvath L, Grimison P, Park SB (2019) Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. Support Care Cancer 27(10):3849–3857
pubmed: 30756229 doi: 10.1007/s00520-019-04680-w
Kneis S, Wehrle A, Müller J, Maurer C, Ihorst G, Gollhofer A, Bertz H (2019) It’s never too late—balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial. BMC Cancer 19(1):414
pubmed: 31046719 pmcid: 6498676 doi: 10.1186/s12885-019-5522-7
Amireault S, Godin G, Lacombe J, Sabiston CM (2015) Validation of the Godin-Shephard Leisure-Time Physical Activity Questionnaire classification coding system using accelerometer assessment among breast cancer survivors. J Cancer Surviv 9(3):532–540
pubmed: 25666749 doi: 10.1007/s11764-015-0430-6
Bliss JW, Lavery JA, Underwood WP, Chun SS, Fickera GA, Lee CP, Corcoran S, Maloy MA, Polubriaginof FC, Kelly DW et al (2022) Impact of exercise on susceptibility and severity of COVID-19 in patients with cancer: a retrospective study. Cancer Epidemiol Biomarkers Prev 31(5):1036–1042
pubmed: 35506245 pmcid: 9135110 doi: 10.1158/1055-9965.EPI-21-1186
Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, George SM, Olson RD (2018) The physical activity guidelines for Americans. JAMA 320(19):2020–2028
pubmed: 30418471 pmcid: 9582631 doi: 10.1001/jama.2018.14854
Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327–333
pubmed: 27510185 pmcid: 5509538 doi: 10.1007/s10549-016-3939-0
R Core Team (2022) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Núñez de Arenas-Arroyo S, Cavero-Redondo I, Torres-Costoso A, Reina-Gutiérrez S, Lorenzo-García P, Martínez-Vizcaíno V (2023) Effects of exercise interventions to reduce chemotherapy-induced peripheral neuropathy severity: a meta-analysis. Scand J Med Sci Sports 33(7):1040–1053
pubmed: 36972017 doi: 10.1111/sms.14360
Ligibel JA, Bohlke K, May AM, Clinton SK, Demark-Wahnefried W, Gilchrist SC, Irwin ML, Late M, Mansfield S, Marshall TF et al (2022) Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol 40(22):2491–2507
pubmed: 35576506 doi: 10.1200/JCO.22.00687
Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Schep G, Husson O (2015) Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv 9(3):512–522
pubmed: 25876556 doi: 10.1007/s11764-015-0427-1
Streckmann F, Balke M, Cavaletti G, Toscanelli A, Bloch W, Décard BF, Lehmann HC, Faude O (2022) Exercise and neuropathy: systematic review with meta-analysis. Sports Med 52(5):1043–1065
pubmed: 34964950 doi: 10.1007/s40279-021-01596-6
Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH et al (2019) Exercise guidelines for cancer survivors: consensus statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc 51(11):2375–2390
pubmed: 31626055 pmcid: 8576825 doi: 10.1249/MSS.0000000000002116
Guo S, Han W, Wang P, Wang X, Fang X (2023) Effects of exercise on chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis. J Cancer Surviv 17(2):318–331
pubmed: 35149899 doi: 10.1007/s11764-022-01182-3
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J (2019) Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 20(6):1451
pubmed: 30909387 pmcid: 6471666 doi: 10.3390/ijms20061451
Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, Fung C, Janelsins MC, Asare M, Lin PJ et al (2018) Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 26(4):1019–1028
pubmed: 29243164 doi: 10.1007/s00520-017-4013-0
Colvin LA (2019) Chemotherapy-induced peripheral neuropathy: where are we now? Pain 160(Suppl 1):S1–S10
pubmed: 31008843 pmcid: 6499732 doi: 10.1097/j.pain.0000000000001540
Boland EG, Selvarajah D, Hunter M, Ezaydi Y, Tesfaye S, Ahmedzai SH, Snowden JA, Wilkinson ID (2014) Central pain processing in chronic chemotherapy-induced peripheral neuropathy: a functional magnetic resonance imaging study. PLoS ONE 9(5):e96474
pubmed: 24821182 pmcid: 4018287 doi: 10.1371/journal.pone.0096474
Nudelman KN, McDonald BC, Wang Y, Smith DJ, West JD, O’Neill DP, Zanville NR, Champion VL, Schneider BP, Saykin AJ (2016) Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol 34(7):677–683
pubmed: 26527786 doi: 10.1200/JCO.2015.62.1276
Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA (2011) The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11(9):607–615
pubmed: 21818123 doi: 10.1038/nri3041
Andersen Hammond E, Pitz M, Shay B (2019) Neuropathic pain in taxane-induced peripheral neuropathy: evidence for exercise in treatment. Neurorehabil Neural Repair 33(10):792–799
pubmed: 31342880 doi: 10.1177/1545968319860486
Holschneider DP, Yang J, Guo Y, Maarek JM (2007) Reorganization of functional brain maps after exercise training: importance of cerebellar-thalamic-cortical pathway. Brain Res 1184:96–107
pubmed: 17964551 pmcid: 2692362 doi: 10.1016/j.brainres.2007.09.081
Armada-da-Silva PA, Pereira C, Amado S, Veloso AP (2013) Role of physical exercise for improving posttraumatic nerve regeneration. Int Rev Neurobiol 109:125–149
pubmed: 24093610 doi: 10.1016/B978-0-12-420045-6.00006-7
Park JS, Hoke A (2014) Treadmill exercise induced functional recovery after peripheral nerve repair is associated with increased levels of neurotrophic factors. PLoS ONE 9(3):e90245
pubmed: 24618564 pmcid: 3949693 doi: 10.1371/journal.pone.0090245
Stagg NJ, Mata HP, Ibrahim MM, Henriksen EJ, Porreca F, Vanderah TW, Philip Malan Jr T (2011) Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: role of endogenous opioids. Anesthesiology 114(4):940–948
pubmed: 21386701 doi: 10.1097/ALN.0b013e318210f880
Zhang YH, Hu HY, Xiong YC, Peng C, Hu L, Kong YZ, Wang YL, Guo JB, Bi S, Li TS et al (2021) Exercise for neuropathic pain: a systematic review and expert consensus. Front Med (Lausanne) 8:756940
pubmed: 34901069 doi: 10.3389/fmed.2021.756940
Santa Mina D, van Rooijen SJ, Minnella EM, Alibhai SMH, Brahmbhatt P, Dalton SO, Gillis C, Grocott MPW, Howell D, Randall IM et al (2020) Multiphasic prehabilitation across the cancer continuum: a narrative review and conceptual framework. Front Oncol 10:598425
pubmed: 33505914 doi: 10.3389/fonc.2020.598425
Castelli G, Desai KM, Cantone RE (2020) Peripheral neuropathy: evaluation and differential diagnosis. Am Fam Physician 102(12):732–739
pubmed: 33320513
Delanian S, Lefaix JL, Pradat PF (2012) Radiation-induced neuropathy in cancer survivors. Radiother Oncol 105(3):273–282
pubmed: 23245644 doi: 10.1016/j.radonc.2012.10.012
Volaco A, Cavalcanti AM, Filho RP, Précoma DB (2018) Socioeconomic status: the missing link between obesity and diabetes mellitus? Curr Diabetes Rev 14(4):321–326
pubmed: 28637406 doi: 10.2174/1573399813666170621123227

Auteurs

Kirin Saint (K)

University of Michigan Medical School, Ann Arbor, MI, USA.

David Nemirovsky (D)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Alexie Lessing (A)

Stony Brook University, Stony Brook, NY, USA.

Yuan Chen (Y)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Mingxiao Yang (M)

Dana-Farber Cancer Institute, Boston, MA, USA.

Whitney P Underwood (WP)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Mary Lou Galantino (ML)

Stockton University, Galloway, NJ, USA.
University of Witwatersrand, Johannesburg, South Africa.
Weill Cornell Medicine, New York, NY, USA.

Lee W Jones (LW)

Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weill Cornell Medicine, New York, NY, USA.

Ting Bao (T)

Leonard P. Zakim Center for Integrative Therapies and Healthy Living, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA. ting_bao@dfci.harvard.edu.

Classifications MeSH